Compare SBCF & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | PGEN |
|---|---|---|
| Founded | 1926 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2009 | 2013 |
| Metric | SBCF | PGEN |
|---|---|---|
| Price | $32.74 | $6.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $36.71 | $13.65 |
| AVG Volume (30 Days) | 782.2K | ★ 4.6M |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 10.56 | N/A |
| EPS | ★ 0.84 | 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $29.79 | $2,365.68 |
| Revenue Next Year | $6.00 | $85.75 |
| P/E Ratio | ★ $39.05 | $228.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.69 | $3.04 |
| 52 Week High | $36.27 | $8.98 |
| Indicator | SBCF | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.64 | 39.73 |
| Support Level | $30.84 | $6.57 |
| Resistance Level | $34.62 | $7.44 |
| Average True Range (ATR) | 0.54 | 0.43 |
| MACD | 0.15 | -0.17 |
| Stochastic Oscillator | 82.32 | 14.55 |
Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.